Graham Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

Graham Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$87.2K	Sell	51,592 -24,773	-32%	-$109K	﹤0.01%	1056
2025 Q4	$396K	Buy	76,365 +30,443	+66%	+$156K	0.01%	727
2025 Q3	$240K	Buy	+45,922	New	+$239K	﹤0.01%	970
2023 Q4	–	Sell	-10,123	Closed	-$67.6K	–	973
2023 Q3	$67.6K	Buy	+10,123	New	+$75.1K	﹤0.01%	953
2022 Q4	–	Sell	-41,590	Closed	-$222K	–	1028
2022 Q3	$222K	Sell	41,590 -795	-2%	-$4.77K	0.01%	971
2022 Q2	$169K	Buy	+42,385	New	+$146K	0.01%	935
2022 Q1	–	Sell	-10,047	Closed	-$40K	–	882
2021 Q4	$40K	Buy	+10,047	New	+$76.6K	﹤0.01%	525

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Graham Capital Management's ALDX Position: Q1 2026 in Review

Graham Capital Management reduced its Aldeyra Therapeutics (ALDX) stake by 32% in Q1 2026, selling an estimated $109K and leaving 51,592 shares worth $87.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1056.

Graham Capital Management first reported a position in ALDX in Q4 2021 and has held it in 7 quarters since. The position peaked at $396K in Q4 2025. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

Graham Capital Management held 51,592 shares of Aldeyra Therapeutics worth $87.2K as of Q1 2026.
Graham Capital Management sold 24,773 Aldeyra Therapeutics shares in Q1 2026, an estimated $109K.
Aldeyra Therapeutics made up ﹤0.01% of Graham Capital Management's portfolio in Q1 2026, its #1056 holding.
Graham Capital Management first reported a position in Aldeyra Therapeutics in Q4 2021 and has held it in 7 quarters since.
Graham Capital Management's Aldeyra Therapeutics position peaked at $396K in Q4 2025.
126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.